1-20 of 60
Kevin Kalinsky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status

Irene Kang, Jamie K. Forschmiedt, Michelle M. Loch, William E. Barlow, Danika L. Lew, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Priya Rastogi, Anne F. Schott, Steven Shak, Priyanka Sharma, Jieling Miao, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky, N. Lynn Henry
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): GS1-04.
https://doi.org/10.1158/1538-7445.SABCS22-GS1-04
Published: 01 March 2023
View article titled, Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
Journal Articles

Abstract P4-01-42: Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 studies

Erika Hamilton, Laura M. Spring, Peter A. Fasching, Sandra Franco, Richard H DeBoer, Javier Cortés, Kevin Kalinsky, Dejan Juric, Aditya Bardia, Sina Haftchenary, Agnes Lteif, Juan Pablo Zarate, Liyi Cen, Patrick Neven
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P4-01-42.
https://doi.org/10.1158/1538-7445.SABCS22-P4-01-42
Published: 01 March 2023
View article titled, Abstract P4-01-42: Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 studies
Journal Articles

Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Erica Stringer-Reasor, Rebecca A. Shatsky, Jo Chien, Anne Wallace, Judy C. Boughey, Kathy S. Albain, Hyo S. Han, Rita Nanda, Claudine Isaacs, Kevin Kalinsky, Zahi Mitri, Amy S. Clark, Christos Vaklavas, Alexandra Thomas, Meghna S. Trivedi, Janice Lu, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van ’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD11-01.
https://doi.org/10.1158/1538-7445.SABCS22-PD11-01
Published: 01 March 2023
View article titled, Abstract PD11-01: PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract OT2-10-03: HCRN BRE 19-433: A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

Mylin A. Torres, Kevin Kalinsky, Erica Stringer-Reasor, Ahmed Elkhanany, Jolinta Lin, David M. Schuster, Sarah Friend, Jeffrey Switchenko, Manali Bhave
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT2-10-03.
https://doi.org/10.1158/1538-7445.SABCS22-OT2-10-03
Published: 01 March 2023
View article titled, Abstract OT2-10-03: HCRN BRE 19-433: A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)
Journal Articles

Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1

Sara Hurvitz, Kevin Kalinsky, Vinod Ganju, Kashif Ali, Laila Agrawal, William Gradishar, George Sledge, Anu Thummala, Arlene Chan, Sophia Frentzas, Joo Hyuk Sohn, Kyong-Hwa Park, Keon Uk Park, Catherine Shannon, Joshua Drago, Sara Tolaney, Hope Rugo, Michael F. Press, Alex Alika, Dong Xu, Janice Lu, Debu Tripathy
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD18-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD18-09
Published: 01 March 2023
View article titled, Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1
Journal Articles

Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score

Laura M. Spring, William E. Barlow, Aditya Bardia, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): HER2-19.
https://doi.org/10.1158/1538-7445.SABCS22-HER2-19
Published: 01 March 2023
View article titled, Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER)
Journal Articles

Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Claudine Isaacs, Rita Nanda, Jo Chien, Meghna S. Trivedi, Erica Stringer-Reasor, Christos Vaklavas, Judy C. Boughey, Amy Sanford, Anne Wallace, Amy S. Clark, Alexandra Thomas, Kathy S. Albain, Laura C. Kennedy, Tara B. Sanft, Kevin Kalinsky, Hyo S. Han, Nicole Williams, Mili Arora, Anthony Elias, Carla Falkson, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, I-SPY Investigators
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): GS5-03.
https://doi.org/10.1158/1538-7445.SABCS22-GS5-03
Published: 01 March 2023
View article titled, Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Journal Articles

Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007)

Yara Abdou, William E. Barlow, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Stephen K. Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Anne F. Schott, Steven Shak, Priyanka Sharma, Danika L. Lew, Jieling Miao, Joseph M. Unger, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): GS1-01.
https://doi.org/10.1158/1538-7445.SABCS22-GS1-01
Published: 01 March 2023
View article titled, Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007)
Journal Articles

Abstract P2-20-15: Proteolytic regulation of CD73 by TRIM2 orchestrates tumor immunogenicity

Ziyi Fu, Yueming Zhu, Kevin Kalinsky, Yong Wan
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-20-15.
https://doi.org/10.1158/1538-7445.SABCS22-P2-20-15
Published: 01 March 2023
View article titled, Abstract P2-20-15: Proteolytic regulation of CD73 by TRIM2 orchestrates tumor immunogenicity
Journal Articles

Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01

Aditya Bardia, Kevin Kalinsky, Junji Tsurutani, Erika Hamilton, Joo Hyuk Sohn, Kyong Hwa Park, Yeon Hee Park, Seock-Ah Im, Keun Seok Lee, Daisy Dastur, Vincent Haddad, Sabrina Khan, Binghe Xu, Barbara Pistilli, Hope Rugo
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT1-03-04.
https://doi.org/10.1158/1538-7445.SABCS22-OT1-03-04
Published: 01 March 2023
View article titled, Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01
Journal Articles

Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status

Michelle M. Loch, Jamie K. Forschmiedt, Irene M. Kang, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Priya Rastogi, Anne F. Schott, Steven Shak, Priyanka Sharma, Danika L. Lew, Jieling Miao, William E. Barlow, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky, N. Lynn Henry
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-05-06.
https://doi.org/10.1158/1538-7445.SABCS22-P6-05-06
Published: 01 March 2023
View article titled, Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status
Journal Articles

Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancers

Tao Qing, Thomas Karn, Mariya Rozenblit, Julia Foldi, Michal Marczyk, Naing Lin Shan, Kim Blenman, uwe Holtrich, Kevin Kalinsky, Funda Meric-Bernstam, Lajos Pusztai
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD9-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD9-09
Published: 01 March 2023
View article titled, Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative breast cancers
Journal Articles

Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP)

Jennifer Rosenbluth, Christopher J. Schwartz, Tam Binh Bui, Shruti Warhadpande, Pravin Phadatare, Sigal Eini, Michael Bruck, Julissa Molina-Vega, Kami Pullakhandam, Nicole Schindler, Lamorna A. Brown Swigart, Christina Yau, Gillian Hirst, Rita Mukhtar, Karthik V. Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Cheryl A. Ewing, Jasmine M. Wong, Michael D. Alvarado, Laura Van’t Veer, Laura J. Esserman, Jo Chien
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-09-01.
https://doi.org/10.1158/1538-7445.SABCS22-P3-09-01
Published: 01 March 2023
View article titled, Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP)
Journal Articles

Abstract PD13-09: PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors

Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD13-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD13-09
Published: 01 March 2023
View article titled, Abstract PD13-09: PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors
Journal Articles

Abstract OT1-03-01: XMT-1660: A Phase 1b trial of a B7-H4 targeted Antibody Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers

Erika Hamilton, Arvind Chaudhry, Alexander I. Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo S. Han, Amy Weise, Aubri Marchesani, Kate Josephs, Chu Ri Shin, Kevin Kalinsky
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT1-03-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT1-03-01
Published: 01 March 2023
View article titled, Abstract OT1-03-01: XMT-1660: A Phase 1b trial of a B7-H4 targeted Antibody Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers
Journal Articles

Abstract P6-01-23: Role of tumor infiltrating lymphocytes and PD-L1 expression in the response to eribulin and pembrolizumab in metastatic triple negative breast cancer (mTNBC) on the ENHANCE1 trial

Mathew Kearney, Hua Guo, Rami Vanguri, Qi Wang, Michelle Garlin, Courtney Connelly, Kevin Kalinsky, Eileen P. Connolly
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-01-23.
https://doi.org/10.1158/1538-7445.SABCS22-P6-01-23
Published: 01 March 2023
View article titled, Abstract P6-01-23: Role of tumor infiltrating lymphocytes and PD-L1 expression in the response to eribulin and pembrolizumab in metastatic triple negative breast cancer (mTNBC) on the ENHANCE1 trial
Journal Articles

Abstract P6-01-20: Luminal androgen receptor subtype and M2 macrophage signatures strongly associate with low pathological complete response rates and poor outcomes in patients with triple negative breast cancer receiving neoadjuvant chemotherapy

Jane Meisel, Eugene Douglass, Kevin Kalinsky, Lyra M. Griffiths, Zaibo Li, Xiaoxian Li
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-01-20.
https://doi.org/10.1158/1538-7445.SABCS22-P6-01-20
Published: 01 March 2023
View article titled, Abstract P6-01-20: Luminal androgen receptor subtype and M2 macrophage signatures strongly associate with low pathological complete response rates and poor outcomes in patients with triple negative breast cancer receiving neoadjuvant chemotherapy
Journal Articles

Abstract P3-07-22: Presurgical Trial of Metformin plus Atorvastatin in Women with Operable Breast Cancer

Julia E. McGuinness, Katherine D. Crew, Meghna S. Trivedi, Melissa K. Accordino, Shing M. Lee, Hua Guo, Hanina Hibshoosh, Dawn Hershman, Kevin Kalinsky
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-22.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-22
Published: 01 March 2023
View article titled, Abstract P3-07-22: Presurgical Trial of Metformin plus Atorvastatin in Women with Operable Breast Cancer
Journal Articles

Abstract PD16-06: Early MRI and PET biomarkers for hormone receptor-positive/HER2-negative early-stage breast cancer in the setting of neoadjuvant endocrine therapy and neoadjuvant chemotherapy in the I-SPY 2 TRIAL

Natsuko Onishi, Ella F. Jones, Julia Carmona-Bozo, Jessica E. Gibbs, Teffany Joy Bareng, Julissa Molina-Vega, Kimberly M. Ray, Courtney Lawhn Heath, Bonnie N. Joe, Wen Li, Jiachao Liang, David C. Newitt, Diane Heditsian, Susie Brain, Denise M. Wolf, Christina Yau, Karthik V. Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Rita Mukhtar, the I-SPY 2 Imaging Working Group and the I-SPY 2 Consortium, Laura J. Esserman, Jo Chien, Nola M. Hylton
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD16-06.
https://doi.org/10.1158/1538-7445.SABCS22-PD16-06
Published: 01 March 2023
View article titled, Abstract PD16-06: Early MRI and PET biomarkers for hormone receptor-positive/HER2-negative early-stage breast cancer in the setting of neoadjuvant endocrine therapy and neoadjuvant chemotherapy in the I-SPY 2 TRIAL
Journal Articles

Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy

François-Clément Bidard, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen KL Chia, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Yeon Hee Park, Steven Fox, Xiaochun Liu, Andrew Walding, Cynthia Huang Bartlett, Nick C Turner
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-11-05.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-11-05
Published: 15 February 2022
View article titled, Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable <em>ESR1</em>m who have not experienced disease progression on first-line therapy